Ameliorative Effect of Curcumin Nanoparticles against Monosodium Iodoacetate-Induced Knee Osteoarthritis in Rats

Hadeer M. Hamdalla1, Rasha R. Ahmed1, Sanaa R. Galaly1, Ibrahim A. Naguib2, Badrah S. Alghamdi3,4, Osama M. Ahmed5, Ahmed Farghali6, and Manal Abdul-Hamid1

1Cell Biology, Histology and Genetics Division, Department of Zoology, Faculty of Science, Beni-Suef University, P.O. Box 62521, Beni-Suef, Egypt
2Department of Pharmaceutical Chemistry, College of Pharmacy, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia
3Department of Physiology, Neuroscience Unit, Faculty of Medicine, King Abdulaziz University, Jeddah 22252, Saudi Arabia
4Pre-Clinical Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia
5Physiology Division, Zoology Department, Faculty of Science, Beni-Suef University, P.O. Box 62521, Beni-Suef, Egypt
6Department of Material Science and Nanotechnology, Faculty of Postgraduate Studies for Advanced Science, Beni-Suef University, Egypt

Correspondence should be addressed to Badrah S. Alghamdi; basalghamdi@kau.edu.sa and Manal Abdul-Hamid; medo_bio@yahoo.com

Received 20 July 2022; Revised 4 September 2022; Accepted 26 September 2022; Published 14 October 2022

Aim. This study is aimed at evaluating the use of curcumin-loaded polylactic-co-glycolic acid nanoparticles (CUR-loaded PLGA NPs) as a treatment against monosodium iodoacetate- (MIA-) induced knee OA.

Materials and Methods. Eighteen rats were assigned to three groups (n = 6), namely, normal control group that received intra-articular injections (IAIs) of saline, an OA control group that received IAIs of MIA (2 mg/50 μL), and a treatment group (MIA+CUR-loaded PLGA NPs) that received IAIs of CUR-loaded PLGA NPs (200 mg/kg b.wt).

Results. The CUR NP treatment against knee OA alleviated radiographic alternations and histopathological changes and inhibited the upregulation in the serum levels of interleukin-1β, tumor necrosis factor-α, interleukin-6, and transforming growth factor-beta and the downregulation in interleukin-10. CUR NP-treated joints also decreased the mRNA expression of nuclear factor-kappa B and inducible nitric oxide synthase and the protein expression of matrix metalloproteinase-13 and caspase-3. Finally, CUR-loaded PLGA NP treatment mitigated the loss of type II collagen, which resulted in a significant reduction in malondialdehyde level and increased the glutathione content and superoxide dismutase activity compared with that of the OA group.

Conclusion. This study demonstrated that the administration of CUR NPs could provide effective protection against MIA-induced OA and knee joint histological deteriorated changes due to its anti-inflammatory, antioxidant, and antiapoptotic properties.

1. Introduction

Osteoarthritis (OA) is a progressive and degenerative illness that happens in the whole joint and can result in articular cartilage degeneration, subchondral bone thickening, synovium inflammation, osteophyte formation, and meniscal degeneration [1]. Treatments for OA are mainly divided into three categories: nonpharmacological treatments, pharmacological treatments limited to analgesics and/or nonsteroidal anti-inflammatory drugs (NSAIDs), and surgical treatments [2]. Current available medications for OA, except joint replacement surgery, are essentially palliative and cannot hinder articular cartilage degradation [3]. Furthermore, long-term use of NSAIDs can cause adverse gastrointestinal,
renal, and cardiovascular effects [4]. This calls for the development of a structural OA disease drug that is safe, provides symptomatic relief, and hinders the progression of cartilage degeneration.

Curcumin (CUR) (diferuloylmethane), a polyphenol compound obtained from turmeric, is a naturally available molecule that has robust anti-catabolic, antioxidant, anti-inflammatory, and anti-atherosclerotic properties [5–7]. Accordingly, CUR seems to be a promising approach in OA therapy. Nevertheless, the therapeutic efficiency of CUR is extremely restricted because of its low water solubility and limited oral bioavailability [8]. Nevertheless, studies have reported that CUR’s biological activity could be efficiently enhanced using nanotechnology-based drug delivery [9, 10]. Various studies have explored CUR nanoparticles (NPs) and CUR encapsulation with various substances such as liposomes and polymers to overcome its inherent drawbacks [11, 12]. Polylactic-co-glycolic acid (PLGA) is considered as an effective biodegradable polymeric NPs that was authorized by US Food and Drug Administration for use in drug delivery systems due to its low toxicity, controlled and sustained-release properties, and biocompatibility with tissue and cells [13, 14].

On the other hand, the intra-articular route for drug delivery has significant potency and fewer systemic side effects compared to that of oral delivery [15]. Accordingly, this study was designed to explore the possible feasibility of the intra-articular injections (IAIs) of CUR-loaded PLGA NPs to treat monosodium iodoacetate- (MIA-) induced knee OA in a rat model.

2. Materials and Methods

2.1. Animals. This study used mature male Wistar rats weighing 130–150 g, which were kept in a standard 12:12 light/dark cycle in well-ventilated rooms. One week before initiating the experiments, the rats were housed in sterilized cages to be adapted to the laboratory with free access to water and pellets. All methods for handling, use, and euthanasia of the animals in this study were certified by the Experimental Animal Ethics Committee of Faculty of Science, Beni-Suef University, Egypt, and the ethical authorization number is BSU/FS/2018/15.

2.2. Induction of OA. MIA was obtained from Sigma-Aldrich (St. Louis, MO, USA) and dispersed in sterile saline. Under diethyl ether anesthesia, all rats, except the normal control group, received a single intra-articular injection of 50 μL of saline containing MIA (2 mg) into the left side knee joint, as previously described by Ragab et al. [16].

2.3. Preparation of CUR-Loaded PLGA NPs. PLGA, which is poly(D, L-lactide-co-glycolide) with lactide: glycolide 50:50, molecular weight (24,000), inherent viscosity (1.13 dL/g), and formula \( \text{C}_n \text{H}_{2n+2} \text{O}_{2n+1} \), was obtained from Sigma-Aldrich (St. Louis, MO, USA). Besides, curcumin, chloroform, polyvinyl alcohol (PVA; MW 30,000–70,000), and ethanol were all purchased from Sigma-Aldrich (St. Louis, MO, USA) as well.

CUR-loaded PLGA NPs were synthesized by solvent solid-in-oil-in-water emulsion (s/o/w) evaporation based on the method published by Niazvand et al. [17]. The PLGA/chloroform solution (oil phase) was prepared by dissolving 60 mg of PLGA in 1 mL of chloroform. Then, 6 mg of CUR was added to the solution and sonicated, resulting in a solid/oil emulsion. Thereafter, ethanol and 2% PVA (1:1) was added to the emulsion and sonicated for 10 min to produce a solid/oil/weight (s/o/w) emulsion. The s/o/w emulsion was further sonicated and agitated by a magnetic stirrer for 5–6 h to evaporate the solvent (chloroform). The sample was subsequently centrifuged for 10 min at 15,000 g before being rinsed three times using distilled water. The sample was allowed to freeze-dry for 24 h to get a dry powder. The obtained NPs were kept at 4°C.

2.4. Characterization of CUR-Loaded PLGA NPs. The surface morphology of CUR-loaded PLGA NPs was investigated with a scanning electron microscope (Zeiss Sigma 500 VP Analytical FE-SEM, Carl Zeiss Germany) and X-ray diffraction (XRD) analysis (model no: 202964, Panalytical Empyrean company). In addition, their zeta potential and size were detected by Malvern (Malvern Instruments Ltd) following the method by Moaty et al. [18].

2.5. Experimental Design. As described in Figure 1, the rats were randomly allocated into three groups \((n = 6)\). At 0, 14, 18, 22, and 26 days, the normal control group took IAIs of 50 μL of saline into the left side knee joint, whereas the other two groups received IAIs of MIA (2 mg) into the left side knee joints on day 0. Then, rats in the OA control group were given saline IA injections on days 14, 18, 22, and 26, while the treatment group (MIA+CUR-loaded PLGA NPs) received intra-articular injections of CUR-loaded PLGA NPs at a dose of 200 mg/kg MIA and CUR-loaded PLGA NPs injection doses were based on the previous studies by Ragab et al. [16] and Niazvand et al. [17], respectively.

2.6. Knee Diameter Measurement (Swelling). A manual caliper was used to assess the variations in the anterior-posterior diameter values of the knee joints among all groups [19]. The measurements were obtained on days 0, 7, 14, 21, and 28 after MIA injection.

2.7. X-Ray Examination. On day 30 post-MIA injection, animals from all groups were anesthetized using diethyl ether, and both hind limbs were extended and fixed on the table with tape. Radiographs of the left knees (anterior-posterior) were captured using an X-ray device with a 60 cm focal film distance at 55 kV and 3 mA.

2.8. ELISA Evaluation. Inflammatory status was evaluated in all groups by measuring the serum proinflammatory cytokines, tumor necrosis factor-α (TNF-α) (cat# MBS697379), transforming growth factor-beta (TGF-β) (cat # MBS8819920), interleukin-1β (IL-1β) (cat# MBS697409) and the anti-inflammatory cytokine IL-10 (cat # MBS2707969) using MyBioSource Inc., San Diego, CA, USA, following the manufacturer’s instructions.
2.9. Evaluation of Antioxidant Markers and Oxidative Stress

2.9.1. Determination of Lipid Peroxidation Level. Malondialdehyde (MDA) that was generated through the breakdown of polyunsaturated fatty acids was used as an index for assessment of the extent of lipid peroxidation in serum following the method of Preuss et al. [20].

2.9.2. Determination of Glutathione (GSH) Content and Superoxide Dismutase (SOD) Activity. GSH content in serum was assayed following the procedure of Beutler et al. [21], while the detection of serum SOD relied on the enzyme’s capacity to prevent the phenazine methosulphate-mediated decrease of nitroblue tetrazolium dye according to Nishikimi et al. [22].

2.10. Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) Assay. The mRNA levels of nuclear factor-kappa B (NF-κB), type II collagen, and inducible nitric oxide synthase (iNOS) were determined by real-time qRT-PCR, for which the Qiagen tissue extraction kit (Qiagen, USA) was applied for the total RNA isolation. Then, 0.5–2 μg total RNA was applied for cDNA synthesis utilizing a Fermentas kit (USA). Applied Biosystem software version 3.1 (StepOne, USA) was utilized for real-time qPCR amplification and analysis. The qRT-PCR assay was done with primer sets optimized for the annealing temperature. The sequences of the primers are listed in Table 1.

2.11. Western Blot Assay. The impact of CUR-loaded PLGA NPs on the protein expression levels of NF-κB50 and NF-κB65 and cleaved caspase-3 was investigated using knee samples maintained at 80°C. Briefly, all samples were homogenized in a radio-immunoprecipitation (RIPA) buffer supplemented with proteinase inhibitors and centrifuged, and the protein concentration was assayed with Bradford assay in the obtained clear supernatant. Proteins (30 mg) were separated on SDS-PAGE, moved to nitrocellulose membranes, and blocked with TRIS using 3% bovine serum albumin and a Tween 20 (TBST) buffer at ambient temperature for 1 hour. Subsequently, membranes were left in the incubator with primary antibodies against NFkBp50 (Cat# 14-6732-81; eBioscience), NF-kBp65 (Cat# 14-6731-81, eBioscience), and cleaved caspase-3 (cat # PA5-114687, Thermo Fisher Scientific). Following the washing with TBST, the prepared membranes were left in the incubator with the corresponding secondary antibodies, after which a chemiluminescence kit (BIORAD, USA) was applied. The developed blots were scanned, and image analysis software was utilized to measure the obtained band intensity of the targeted proteins against the control sample after being normalized by beta-actin on a Chemi Doc MP imager.

2.12. Histopathological Analysis. The left knee joints were assembled from all groups, followed by fixing in 10% neutral buffered formalin for 48 hours, and then decalcified using 20% EDTA for two weeks. The joints were excised sagittal and processed to get 4–6 μm paraflin-embedded sections. Obtained sections were then stained using hematoxylin and eosin (H&E) before being examined under a light microscope.

2.13. Immunohistochemistry Analysis. The sections were stained following the streptavidin-biotin-peroxidase staining method [23]. Paraffin tissue sections (4–6 μm) were deparaffinized in xylene and then rehydrated in ethanol.
Endogenous peroxidase and nonspecific binding sites for antibodies were suppressed by treating the sections for 10 min with hydrogen peroxide (0.3%) and for 20 min with 5% normal bovine serum (1 : 5 diluted tris buffer saline [TRIS]) at ambient temperature, respectively. Obtained sections were rinsed with PBS, and then, 10% normal goat serum was applied for 30 min to minimize nonspecific binding. Obtained sections were then incubated in anti MMP13 primary antibody (cat no: GB11247; Servicebio, China) for 1 h, followed by incubation in streptavidin horseradish peroxidase (Dako-K0690) and biotinylated secondary antibody (Dako Universal LSAB Kit) for 15 min and then incubated in 3-diaminobenzidine tetrahydrochloride (Sigma-D5905; Sigma-Aldrich Company Ltd., Gillingham, UK) substrate kit for 10 min to achieve immunolabelling. Afterward, the nuclei were stained using Harry’s hematoxylin stain, dehydrated ethanol, cleared in xylene, and then mounted in DPX. Antibody binding was observed with high-power light microscopy.

2.14. Statistical Analysis. Statistical analyses were performed using SPSS software version 25.0 (SPSS Inc., Chicago, IL, USA). All results are presented as means (M) ± standard errors of means (SEMs), with \( P < 0.05 \) meaning a statistically significant difference.

3. Results

3.1. Characterization of CUR-Loaded PLGA NPs. In this study, the prepared CUR-loaded PLGA NPs were shown using a scanning electron microscope micrograph (Figure 2), which were spherically shaped. Meanwhile, the XRD pattern of CUR-loaded PLGA NPs (Figure 3) showed an absence of

### Table 1: Primer sequences for NF-κB, iNOS, and type II collagen mRNA.

| Target gene       | Primer sequence                                                                 |
|-------------------|---------------------------------------------------------------------------------|
| NF-κB             | Forward primer: 5′-CATTGAGGTGTATTTTCACGG-3′  
                    Reverse primer: 5′-GGCAAAGTGCCATTTGGTTC-3′                                |
| iNOS              | Forward primer: 5′-GACCAGAAACTGTCTCACCTG-3′                                     |
| Type II collagen  | Forward primer: 5′-GAGTGGAAGAGCGGAGACTACTG-3′                                    |
| Beta-actin        | Forward primer: 5′-TGTTTAGACCTTCAACACC-3′                                       |

There were six samples in each group, and data are described as means ± SEM. For each parameter, means (which have different superscript symbols) are statistically significant at \( P < 0.05 \).
NPs were 265.2 nm and in the polymer matrix. Further, the average size (Figure 4(a)) implying that these NPs were in the disordered-crystalline marked crystalline domains in CUR-loaded PLGA NPs, di loaded PLGA NP groups. At each period, the means, which have normal control, monosodium iodoacetate (MIA), and MIA+CUR.

3.2. Effect of CUR-Loaded PLGA NPs on Swelling (Knee Diameter Measurements). As shown in Figure 5, MIA induced an increase in the knee diameters of the OA control and treatment groups when compared to the measurements before the injection. Nevertheless, two weeks of CUR-loaded PLGA NP IAIs markedly reduced swelling in the left knee joints.

3.3. Effect of CUR-Loaded PLGA NPs Using X-Ray Imaging. Radiographic detection was carried out to observe changes in the knee joints after CUR-loaded PLGA NP treatment. Compared to that of the normal control group (Figure 6(a)), knee joints in the OA group (Figure 6(b)) had a narrow joint space and deformed articular surface. Meanwhile, the CUR-loaded PLGA NP treatment considerably hindered MIA-induced knee OA progression and attenuated joint destruction, in that the joints of the treated group (Figure 6(c)) showed a little degree of narrowing, and no obvious sclerosis and osteophyte formation was detected.

3.4. Effect of CUR-Loaded PLGA NPs on the Serum Levels of TNF-ɑ, IL-1β, IL-6, TGF-β, and IL-10. The MIA-treated group (Table 2) showed a significant increase in serum TNF-ɑ, IL-6, IL-1β, and TGF-β levels and a decrease in IL-10 levels compared to those of the normal control group (P < 0.05). Meanwhile, the OA knee joints from the treatment group showed a marked reduction in TNF-ɑ, IL-6, IL-1β, and TGF-β levels, along with an elevation in IL-10 levels as compared to those of the OA group.

3.5. Effect of CUR-Loaded PLGA NPs on Lipid Peroxidation and Antioxidant Status. The enhanced level of serum lipid peroxidation product (MDA) in MIA-treated knee joints was accompanied by a substantial reduction in GSH level and SOD activity. Meanwhile, CUR-loaded PLGA NP IAIs significantly lowered the level of MDA and boosted the GSH content and SOD activity (Table 3).

3.6. Effect of CUR-Loaded PLGA NPs on NF-κB, iNOS, and Type II Collagen mRNA Expression. OA knee joints showed a marked (P < 0.05) elevation in the mRNA expression levels of NF-κB and iNOS, along with a significant decline in type II collagen compared with those of the normal group (Table 4). Moreover, OA knee joints treated with CUR exhibited a significant (P < 0.05) downregulation in NF-κB and iNOS levels and inhibited the loss of type II collagen mRNA expression level in comparison with that in OA control rats.

3.7. Effect of CUR-Loaded PLGA NPs on the Protein Expression Levels of NF-κB p50 and NF-κB p65. Western blot analysis shows that the protein expression levels of NF-κB p50 and NF-κB p65 (Figures 7) were elevated post-MIA administration when compared with the normal control. However, CUR-loaded PLGA NP treatment significantly diminished the protein expression of NF-κB p50 and NF-κB p65 in the OA knee joints as compared to the MIA group.

3.8. Effect of CUR-Loaded PLGA NPs on Cleaved Caspase-3 Protein Expression. The protein level of cleaved caspase-3 (Figure 8) in the knee joint was estimated with western blotting. OA rats demonstrated a marked increase in cleaved caspase-3 level relative to those in the normal control group, while OA rats injected with CUR-loaded PLGA NPs revealed a marked downregulation in the cleaved caspase-3 level compared with those in the OA control group.

3.9. Effect of CUR-Loaded PLGA NPs on the Histopathological Evaluation. H&E sections of the articular
cartilage showed that chondrocytes in the normal control group were placed neatly, and the dyeing was uniform (Figure 9(a)). In the OA control group, obtained sections had a myriad of pathological alternations such as cracks, fibrillation, disorderly arranged cells, empty lacunae, hyperchromatic nuclei, and a magnificant reduction in the number of chondrocytes (Figures 9(b)–9(d)). In contrast, the MIA+CUR-loaded PLGA NP group (Figures 9(e)) showed a notable decrease in the severity of cartilage degradation, as the CUR treatment offered effective protection against OA progression. MIA+CUR-loaded PLGA NP-treated cartilage appeared to have a smooth surface, orderly arranged chondrocytes, less loss of cells, and intact subchondral bone compared to those of MIA-treated cartilages without treatment.

Table 2: Effect of CUR-loaded PLGA NPs on the serum levels of TNF-α, IL-1β, IL-6, TGF-β, and IL-10 in MIA-induced OA in rats.

| Groups                      | Parameters Parameters | Parameters Parameters | Parameters Parameters |
|-----------------------------|------------------------|------------------------|------------------------|
|                             | TNF-α (pg/mL)          | IL-1β (pg/mL)          | IL-6 (pg/mL)           | TGF-β (pg/mL)          | IL-10 (pg/mL)          |
| Normal control              | 20.22 ± 1.1a           | 47.05 ± 2.96a          | 62.78 ± 2.92a          | 115.36 ± 1.36a         | 324.67 ± 10.28c        |
| MIA                         | 261.19 ± 3.47c         | 136.07 ± 4.17c         | 188.9 ± 1.1c           | 260.55 ± 5.26c         | 122.87 ± 4.04a         |
| MIA+CUR-loaded PLGA NPs     | 57.02 ± 1.23b          | 65.57 ± 2.92b          | 94.88 ± 2.62b          | 146.25 ± 5.61b         | 283.57 ± 4.36b         |

There were six samples in each group, and data are described as means ± SEM. For each parameter, means, which have different superscript symbols, are statistically significant at $P < 0.05$.

Figure 6: X-ray image showing the left knee joints (L) of all groups: (a) the normal knee joints; (b) MIA-treated knee joints depicting radiographic alternations such as erosion of the cartilage surface, osteophytes, and joint space narrowing; and (c) MIA+CUR-loaded PLGA NP-treated group, with joints nearly similar to those of the normal control.
Effect of CUR-Loaded PLGA NPs on the Matrix Metalloproteinase-13 (MMP-13) Expression.
MMP-13, a key catabolic enzyme, was immunohistochemically stained in the chondrocytes of the articular cartilage to assess its protein expression. When compared with the normal control group, which almost had no positive staining for

### Table 3: Effect of CUR-loaded PLGA NPs on the serum MDA and GSH levels and SOD activity in MIA-induced OA rats.

| Groups               | Parameters | MDA (nmol/mL) | GSH (mg/dL) | SOD (U/mL) |
|----------------------|------------|---------------|-------------|------------|
| Normal control       |            | 0.84 ± 0.07   | 210.70 ± 10.40 | 263.11 ± 11.71 |
| MIA                  |            | 2.095 ± 0.37  | 9.2213 ± 0.66 | 55.09 ± 9.97  |
| MIA+CUR-loaded PLGA NPs |          | 0.89 ± 0.11  | 41.46 ± 5.99  | 111.16 ± 6.28 |

There were six samples in each group, and data are described as means ± SEM. For each parameter, means, which have different superscript symbols, are statistically significant at $P < 0.05$.

### Table 4: Effect of CUR-loaded PLGA NPs on mRNA relative expression of NF-κB, iNOS, and type II collagen of MIA-induced OA rats.

| Groups                        | NF-κB   | Parameters | iNOS     | Type II collagen |
|-------------------------------|---------|------------|----------|-----------------|
| Normal control                | 0.094 ± 0.0095 | 1 ± 0.0106 | 1.05 ± 0.01 |                |
| MIA                           | 6.72 ± 0.33  | 5.64 ± 0.28 | 0.25 ± 0.06 |                |
| MIA+CUR-loaded PLGA NPs      | 1.94 ± 0.16  | 2.13 ± 0.18 | 0.5 ± 0.04  |                |

There were six samples in each group, and data are described as means ± SEM. For each parameter, means, which have different superscript symbols, are statistically significant at $P < 0.05$.

### Figure 7: Effect of CUR-loaded PLGA NPs on the relative protein expression levels of NF-κB p50 and NF-κB p65 of MIA-induced OA rats.

Means, which have different symbols (letters), are significantly different at $P < 0.05$.

3.10. Effect of CUR-Loaded PLGA NPs on the Matrix Metalloproteinase-13 (MMP-13) Expression. MMP-13, a key catabolic enzyme, was immunohistochemically stained in the chondrocytes of the articular cartilage to assess its protein expression. When compared with the normal control group, which almost had no positive staining for
MMP13 (Figure 10(a)), MIA induced an elevation in MMP-13 content in the articular cartilage of the OA control group (Figure 10(b)). However, sections (Figure 10(c)) showed that the MMP-13 content was notably diminished in the articular cartilage of the MIA+CUR-loaded PLGA NP group as compared to that of the OA control group.

Additionally, our results (Figure 10) demonstrate an increase in cell staining positive for MMP-13 in the articular cartilage following MIA injection compared with that of the normal control group (10.39 ± 0.22 vs. 1.01 ± 0.23, P < 0.05, respectively). However, osteoarthritic rats treated with CUR-loaded PLGA NPs exhibited a marked reduction in MMP-13-positive chondrocytes compared with that of the MIA-treated group without any treatment (5.26 ± 0.74 vs. 10.39 ± 0.22, P < 0.05).

4. Discussion

Currently, evidence shows that there is a significant correlation between the incidence and progression of OA and inflammation, oxidative stress, and excessive catabolic activity [24].

In the current work, we utilized MIA to generate histological and biochemical changes in the articular cartilage that resemble OA conditions in humans [25]. Moreover, in search of inexpensive and beneficial treatments against OA, we prepared CUR-loaded PLGA NPs and investigated their potency against inflammatory mediators, oxidative stress, and chondrocyte apoptosis in MIA-induced OA in a rat model (Figure 11).

The sizes of the CUR-loaded PLGA NP detected in our study were smaller than 300 nm and were consistent with those reported by Gonzales et al. [26]. While the XRD pattern in our study displayed no typical CUR peaks when entrapped in NPs, Khan et al. [27] elucidated that the absence of any noticeable crystalline domains of CUR implies that CUR loaded on PLGA NPs is in the disordered-crystalline phase or the amorphous or the solid-state solubilized form in the polymer matrix. This disordered-crystalline phase, or CUR, inside the polymeric matrix, allows for a controlled release of the encapsulated drug from the NPs.

Following Yabas et al. [28], our radiographic results revealed that CUR NP intra-articular administration markedly lessened the MIA-induced radiographic abnormalities in the knee joints of the treated rats represented by normal joint space and smooth surface of articular cartilage.

The NF-κB signaling pathway is claimed to be one of the main signaling pathways that promote the progression of OA [29]. Although NF-κB stays inactive in the cytoplasm under normal conditions, upon adequate stimulation, e.g., by inflammatory cytokines or the inflammatory microenvironment, IκB kinase (IKK) activity phosphorylates IκB proteins and causes their degeneration, which allows free NF-κB complexes to translocate from the cytoplasm into the nucleus and stimulate a variety of inflammation-related genes. Furthermore, it triggers extracellular matrix degradation, chondrocyte apoptosis, pannus formation, and, eventually, pathological cartilage destruction (Figure 11) [5, 30].

Alternatively, various studies assumed that CUR hinders OA-related inflammation by blocking the NF-κB signaling
pathway and preventing chondrocyte apoptosis [31, 32]. As a result, OA-related inflammation is suppressed and progression is slowed [11, 33, 34].

Subsequently, our study discussed the effect of CUR-loaded PLGA NP IAIIs on NF-κB gene and NF-κB-regulated genes participating in inflammation, such as TNF-α, IL-6, IL-1β, and TGF-β. Our data in harmony with Alhusaini et al. [30] propose that CUR administration blocked NF-κB activation by inhibiting IκB degradation and phosphorylation and suppressing the translocation of NF-κB into the nucleus, thereby impeding the inflammatory response of the cells.

Additionally, in agreement with [35], our presented data revealed that CUR considerably boosted the serum levels of IL-10, a robust anti-inflammatory immunosuppressive and chondroprotective cytokine, indicating its potent anti-inflammatory capacity.

Furthermore, CUR-loaded PLGA NP treatment during OA inhibited the expression of iNOS, which is an inflammation-induced enzyme that catalyzes the production of the proinflammatory mediator nitric oxide (NO), further demonstrating its anti-inflammatory effects. Several *in vivo* and *in vitro* studies [36, 37] have shown that CUR treatment reduces iNOS production in various inflammatory diseases.

**Figure 9:** Photomicrographs of hematoxylin and eosin-(H&E-) stained sections of the left knee joints. (a) shows the normal control group with the normal architecture of the articular cartilage that consists of a noncalcified (NCC) region, which is arranged into superficial (S), transitional (T), and radial (R) zones and calcified (CC) region with a clear intact tidemark in between (scale bar = 200 μm). It also shows subchondral bone (SC) with well-oriented bony trabeculae (arrow). (b)–(d) show the MIA-treated group (osteoarthritic rats), wherein (b) depicts fissures, surface fibrillation (curved arrows), chondrocytes with hyperchromatic nuclei (arrowheads), chondrocytes clusters (thin arrow), marked loss of (matrix and chondrocytes), and degenerated and disorganized bone trabeculae (thick arrows); (c) shows a decrease in articular cartilage thickness, unclear tidemark, an abnormal subchondral with an increase in trabecular thickness, and bone marrow space (BM) containing fewer hematopoietic cells; and (d) shows degeneration (asterisk) and heterogeneous distribution of chondrocytes in the growth plate. (e) and (f) show the treatment group (MIA+CUR-loaded PLGA NPs), wherein (e) displays a marked restoration of the normal structure of articular cartilage with an intact surface, except for some damaged parts (**) and a few hyperchromatic nuclei, an increase in cellularity, a partial improvement in tidemark integrity, and nearly normal bone marrow space (BM) relative to the MIA group (scale bar = 200 μm), and (f) demonstrates neatly and properly aligned and oriented chondrocytes of the growth plate (scale bar = 200 μm).
Most recently, Cheragh-Birjandi et al. [37] postulated that CUR administration can regulate NO levels by suppressing the activation of the N-terminal kinase (JNK), p38, and NF-κB pathways.

NF-κB pathway activation not only upregulates proinflammatory mediators but additionally mediates the chondrocyte activation triggered by the released extracellular matrix (ECM) products, e.g., fibronectin fragments, which...
in turn promote the expression of a variety of matrix-degrading enzymes, including metalloproteinases (MMPs) [38–40]. In the early stage of OA, high upregulation of MMP-13 expression, a prominent catabolic enzyme, leads to severe deterioration of cartilage as it induces type II collagen, which is a reason for nearly 90% of the ECM. The loss of type II collagen is a critical stage that determines the irreversible progression of OA (Figure 11) [41]. Therefore, this study explored MMP-13 and collagen type II expression levels as indicators of the anticatabolic activity of CUR NPs in the OA knee joint.

Herein, IAs of CUR NPs prevented OA exacerbation by diminishing MMP-13 expression [42] and the degradation of type II collagen [6]. Kumar et al. [43] posited that CUR possesses a suppressing effect on MMPs and variable cellular signaling pathways, e.g., Janus kinase STAT and NF-κB/mitogen-activated protein kinase/phosphoinositide 3-kinase, which eventually ameliorate OA and prevent the further damage of the cartilage.

Further, the effect of CUR treatment on cell death in knee OA has also been elucidated. Although apoptosis is a crucial process in keeping the homeostasis of several tissues, the high rate of chondrocyte death is a well-known pathological feature of OA [44]. MIA-induced TNF-α activates the tumor necrosis factor receptor (TNFR) or death receptors, eventually triggering the extrinsic pathway of apoptosis (Figure 11). While Ding et al. [45] postulated that in MIA-induced OA, the intrinsic pathway of apoptosis can be triggered by reactive oxygen species (ROS). ROS accumulation could induce oxidative stress, thus altering mitochondrial function and promoting the excretion of cytochrome c and activation of proapoptotic factors, e.g., caspase-3 [44, 46]. Moreover, mitochondrial impairment was shown to enhance the response to cytokine-induced chondrocyte inflammation by producing ROS and activating NF-κB [47].

Conversely, CUR has been shown to restore mitochondrial functions, scavenge free radicals and ROS [48, 49], and suppress lipid peroxidation [50]. CUR also enhances the activity of other antioxidants such as SOD, catalase, GSH, and glutathione peroxidase in various diseases [30, 51]. Based on these studies, we scrutinized the role of CUR-loaded PLGA NPs in suppressing the activation of the apoptosis mediators related to OA. Our data confirmed the antioxidant efficacy of CUR NPs as they considerably averted the increase in MDA lipid peroxidation product and enhanced the antioxidant status (GSH concentration and SOD activity). Moreover, consistent with the results of Buhrman et al. [52], our results revealed the antiapoptotic efficacy of CUR NPs, as they notably hindered upregulation in caspase-3 levels. The antioxidant, anti-inflammatory, and antiapoptotic potency can be mostly attributed to the hydroxyl, methoxy, α, β-unsaturated carbonyl, or diketone groups present in CUR [53].

MIA-induced knee OA inflammation led to severe histopathological alterations in the architecture of the articular cartilage, such as clefts, disorderly arranged cells, hyperchromatic, and a significant reduction in chondrocyte number [31]. Whereas CUR-loaded PLGA NP treatment did not affect the regeneration of the cells, it halted OA progression by reducing inflammation and chondrocytes apoptosis which is depicted by milder tissue defects and pronounced articular cartilage and subchondral bone integrity. Our findings are consistent with Yabas et al. [28], which revealed that CUR lessened OA severity by restoring the architecture of the knee joint. Wang et al. [54] postulated that CUR moderately enhanced the integrity of the articular cartilage by blocking the NF-κB/hypoxia-inducible factor 2α signaling pathway.

Therefore, current findings suggest that OA-related deteriorations and progression are halted due to the ability of CUR-loaded PLGA NPs to modulate various mediators such as NF-κB, MMP-13, and oxidative stress.

5. Conclusion

Overall, this study demonstrates that intra-articular treatment with CUR-loaded PLGA nanoparticles is a compelling candidate for improving joint health in knee OA due to their anti-inflammatory, anticatabolic, and antioxidant characteristics. However, for clinical applications, further research studies with a longer treatment period and bigger sample size should be carried out to explore its underlying mechanisms.

Abbreviations

Cur: Curcumin
CUR-loaded PLGA: Curcumin-loaded polylactic-co-glycolic acid nanoparticles
ECM: Extracellular matrix
GSH: Reduced glutathione
IL: Interleukin
iNOS: Inducible nitric oxide synthase
MDA: Malondialdehyde
MIA: Monosodium iodoacetate
MMP-13: Matrix metalloproteinase-1
NF-κB: Nuclear factor-kappa B
NO: Nitric oxide
NPs: Nanoparticles
NSAIDs: Nonsteroidal anti-inflammatory drugs
OA: Osteoarthritis
PLGA: Polylactic-co-glycolic acid
PVA: Polyvinyl alcohol
RIPA: Radio-immunoprecipitation assay
ROS: Reactive oxygen species
SDS-PAGE: Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
STAT: Janus kinase signal transduction and activation transcription
TBA: Thiobarbituric acid
TGF-β: Transforming growth factor-beta
TNFR: Tumor necrosis factor receptors
TFN-α: Tumor necrosis factor-α.

Data Availability

The authors confirmed that all data generated or analyzed during this study are included in this published article.
Consent
Informed consent was obtained from all subjects involved in the study.

Conflicts of Interest
The authors declare no conflict of interest.

Authors’ Contributions
RRA, SRG, and MA conceived and designed the experiments. HMH performed the experiments and analyzed the data. IAN, BSA, and OMA provided experimental technical support and assisted in completing the study at different stages. HMH drafted the manuscript. RRA, SRG, and MA finalized the paper. All authors are in agreement with the contents of the manuscript. All authors read and approved the final manuscript.

Acknowledgments
This research work was funded by the Institutional Fund Projects under grant no. (IFPDP-14-22). Therefore, authors gratefully acknowledge the technical and financial support from the Ministry of Education and Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, Saudi Arabia.

References
[1] Z. Zhang, C. Huang, Y. Cao et al., “2021 revised algorithm for the management of knee osteoarthritis—the Chinese viewpoint,” Aging Clinical and Experimental Research, vol. 33, no. 8, pp. 2141–2147, 2021.
[2] O. Bruyère, G. Honvo, N. Veronese et al., “An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO),” Seminars in Arthritis and Rheumatism, vol. 49, no. 3, pp. 337–350, 2019.
[3] Z. Wang, S. Wang, K. Wang, X. Wu, C. Tu, and C. Gao, “Stimuli-sensitive nanotherapies for the treatment of osteoarthritis,” Macromolecular Bioscience, vol. 21, no. 11, article e2100280, 2021.
[4] C. Cooper, R. Chapurlat, N. Al-Daghri et al., “Safety of oral non-selective non-steroidal anti-inflammatory drugs in osteoarthritis: what does the literature say?,” Drugs & Aging, vol. 36, Supplement 1, pp. 15–24, 2019.
[5] Y. Henrotin, A. L. Clutterbuck, D. Allaway et al., “Biological actions of curcumin on articular chondrocytes,” Osteoarthritis and Cartilage, vol. 18, no. 2, pp. 141–149, 2010.
[6] J. Wang, J. Ma, J. H. Gu et al., “Regulation of type II collagen, matrix metalloprotease-13 and cell proliferation by interleukin-1β is mediated by curcumin via inhibition of NF-κB signaling in rat chondrocytes,” Molecular Medicine Reports, vol. 16, no. 2, pp. 1837–1845, 2017.
[7] M. Alagawany, M. Farag, S. Abdelnour, M. Dawood, S. Elnesr, and K. Dhama, “Curcumin and its different forms: a review on fish nutrition,” Aquaculture, vol. 532, article 736030, 2021.
[8] L. Shen, C. C. Liu, C. Y. An, and H. F. Ji, “How does curcumin work with poor bioavailability? Clues from experimental and theoretical studies,” Scientific Reports, vol. 6, no. 1, article 20872, 2016.
[9] P. Anand, A. B. Kunnunakkara, R. A. Newman, and B. B. Aggarwal, “Bioavailability of curcumin: problems and promises,” Molecular Pharmaceuticals, vol. 4, no. 6, pp. 807–818, 2007.
[10] A. Karthikeyan, K. N. Young, M. Moniruzzaman et al., “Curcumin and its modified formulations on inflammatory bowel disease (IBD): the story so far and future outlook,” Pharmaceuticals, vol. 13, no. 4, p. 484, 2021.
[11] S. Bisht, G. Feldmann, S. Soni et al., “Polymeric nanoparticle-encapsulated curcumin (’nanocurcumin’): a novel strategy for human cancer therapy,” Journal of Nanobiotechnology, vol. 5, no. 1, p. 3, 2007.
[12] S. Shome, A. D. Talukdar, M. D. Choudhury, M. K. Bhattacharya, and H. Upadhyaya, “Curcumin as potential therapeutic natural product: a nanobiotechnological perspective,” Journal of Pharmacy and Pharmacology, vol. 68, no. 12, pp. 1481–1500, 2016.
[13] F. S. Tabatabaei Mirakabad, K. Nejati-Koshki, A. Akbarzadeh et al., “PLGA-based nanoparticles as cancer drug delivery systems,” Asian Pacific Journal of Cancer Prevention : APJCP, vol. 15, no. 2, pp. 517–535, 2014.
[14] R. Varela-Fernández, C. Bendicho-Lavilla, M. Martin-Pastor et al., “Design, optimization, and in vitro characterization of ibebe-none-loaded PLGA microspheres for LHON treatment,” International Journal of Pharmaceutics, vol. 616, article 121504, 2022.
[15] M. Cristiano, A. Mancuso, E. Giuliano, D. Cosco, D. Paolino, and M. Fresta, “EtoGel for intra-articular drug delivery: a new challenge for joint diseases treatment,” Journal of Functional Biomaterials, vol. 12, no. 2, p. 34, 2021.
[16] G. H. Ragab, F. M. Halfaya, O. M. Ahmed et al., “Platelet-rich plasma ameliorates monosodium iodoacetate-induced ankle osteoarthritis in the rat model via suppression of inflammation and oxidative stress,” Evidence-based Complementary and Alternative Medicine, vol. 2021, Article ID 6692432, 13 pages, 2021.
[17] F. Niazvand, L. Khorsandi, M. Abbaspour et al., “Curcumin-loaded poly lactic-co-glycolic acid nanoparticles effects on mono-iodoacetate -induced osteoarthritis in rats,” Veterinary Research Forum, vol. 8, no. 2, pp. 155–161, 2017.
[18] S. A. Moaty, A. Farghali, M. Moussa, and R. Khaled, “Remediation of waste water by Co-Fe layered double hydroxide and its catalytic activity,” Journal of the Taiwan Institute of Chemical Engineers, vol. 71, pp. 441–453, 2017.
[19] A. A. Badawi, H. M. El-Laithy, D. I. Nesseem, and S. S. El-Husneny, “Pharmaceutical and medical aspects of hyaluronic acid–ketorolac combination therapy in osteoarthritis treatment: radiographic imaging and bone mineral density,” Journal of Drug Targeting, vol. 21, no. 6, pp. 551–563, 2013.
[20] H. G. Preuss, S. T. Jarrell, R. Scheckenbach, S. Lieberman, and R. A. Anderson, “Comparative effects of chromium, vanadium and gymnema sylvestre on sugar-induced blood pressure elevations in SHR,” Journal of the American College of Nutrition, vol. 17, no. 2, pp. 116–123, 1998.
[21] E. Beutler, O. Duron, and B. M. Kelly, “Improved method for the determination of blood glutathione,” The Journal of Laboratory and Clinical Medicine, vol. 61, pp. 882–888, 1963.
Mediators of Inflammation

[22] M. Nishikimi, N. Appaji, and K. Yagi, “The occurrence of superoxide anion in the reaction of reduced phenazine methosulfate and molecular oxygen,” *Biochemical and Biophysical Research Communications*, vol. 46, no. 2, pp. 849–854, 1972.

[23] K. Petrosyan, R. Tamayo, and D. Joseph, “Sensitivity of a novel biotin-free detection reagent (Powerversion+) for immunohistochemistry,” *Journal of Histotechnology*, vol. 25, no. 4, pp. 247–250, 2002.

[24] K. W. Park, K. M. Lee, D. S. Yoon et al., “Inhibition of microRNA-449a prevents IL-1β-induced cartilage destruction via SIRT1,” *Osteoarthritis and Cartilage*, vol. 24, no. 12, pp. 2153–2161, 2016.

[25] S. V. Naveen, R. E. Ahmad, W. J. Hui et al., “Histology, glycosaminoglycan level and cartilage stiffness in monooiodoacetate-induced osteoarthritis: comparative analysis with anterior cruciate ligament transaction in rat model and human osteoarthritis,” *International Journal of Medical Sciences*, vol. 11, no. 1, pp. 97–105, 2014.

[26] C. M. Gonzales, L. F. Dalmonlin, K. A. da Silva et al., “New insights of turmeric extract-loaded PLGA nanoparticles: development, characterization and in vitro evaluation of antioxidant activity,” *Plant Foods for Human Nutrition*, vol. 76, no. 4, pp. 507–515, 2021.

[27] M. Khan, S. Ahmad, I. Ahmad, and M. Rizvi, “Anti-Proliferative Activity of Curcumin Loaded PLGA Nanoparticles for Prostate Cancer,” in *Nanotechnology Applied To Pharmaceutical Technology*, pp. 267–278, Springer, Cham, 2017.

[28] M. Yabas, C. Orhan, B. Er et al., “A next generation formulation of curcumin ameliorates experimentally induced osteoarthritis in rats via regulation of inflammatory mediators,” *Frontiers in Immunology*, vol. 12, article 609629, 2021.

[29] F. Wang, Z. Guo, and Y. Yuan, “STAT3 speeds up progression of osteoarthritis through NF-kB signaling pathway,” *Experimental and Therapeutic Medicine*, vol. 19, no. 1, pp. 722–728, 2020.

[30] A. Alhusaini, L. Fadda, I. H. Hasan, E. Zakaria, A. M. Alnazi, and A. M. Mahmoud, “Curcumin ameliorates lead-induced hepatotoxicity by suppressing oxidative stress and inflammation, and modulating Akt/GSK-3β signaling pathway,” *Biomolecules*, vol. 9, no. 11, p. 703, 2019.

[31] Y. Zhang and Y. Zeng, “Curcumin reduces inflammation in knee osteoarthritis rats through blocking TLR4/MyD88/NF-kB signal pathway,” *Drug Development Research*, vol. 80, no. 3, pp. 353–359, 2019.

[32] A. Nakahata, A. Ito, R. Nakahara et al., “Intra-articular injections of curcumin monoglucuronide TBP1901 suppresses articular cartilage damage and regulates subchondral bone alteration in an osteoarthritis rat model,” *Cartilage*, vol. 13, Supplement 2, pp. 153s–167s, 2021.

[33] P. Anand, H. B. Nair, B. Sung et al., “Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo,” *Biochemical Pharmacology*, vol. 79, no. 3, pp. 330–338, 2010.

[34] X.-H. Wang, W. Li, X.-H. Wang et al., “Water-soluble substances of wheat: a potential preventer of aflatoxin B1-induced liver damage in broilers,” *Poultry Science*, vol. 98, no. 1, pp. 136–149, 2019.

[35] N. Salah, L. Dubuquoy, R. Carpenter, and D. Betbeder, “Starch nanoparticles improve curcumin-induced production of anti-inflammatory cytokines in intestinal epithelial cells,” *International Journal of Pharmaceutics: X*, vol. 4, article 100114, 2022.

[36] H. Y. Kim, E. J. Park, E. H. Joe, and I. Jou, “Curcumin suppresses Janus kinase-STAT inflammatory signaling through activation of Src homology 2 domain-containing tyrosine phosphatase 2 in brain microglia,” *The Journal of Immunology*, vol. 171, no. 11, pp. 6072–6079, 2003.

[37] S. Cheragh-Birjandi, M. Moghibli, F. Haghighi et al., “Impact of resistance exercises and nano-curcumin on synovial levels of collagenase and nitric oxide in women with knee osteoarthritis,” *Translational Medicine Communications*, vol. 5, pp. 1–6, 2020.

[38] M. B. Goldring, “Chondrogenesis, chondrocyte differentiation, and articular cartilage metabolism in health and osteoarthritis,” *Therapeutic Advances in Musculoskeletal Disease*, vol. 4, no. 4, pp. 269–285, 2012.

[39] K. Yamamoto, H. Okano, W. Miyagawa et al., “MMP-13 is constitutively produced in human chondrocytes and endocytosed with ADAMTS-5 and TIMP-3 by the endocytic receptor LRP1,” *Matrix Biology*, vol. 56, pp. 57–73, 2016.

[40] Q. H. Zhao, L. P. Lin, Y. X. Guo et al., “Matrix metalloproteinase-13, NF-κB p65 and interleukin-1β are associated with the severity of knee osteoarthritis,” *Experimental and Therapeutic Medicine*, vol. 19, no. 6, pp. 3620–3626, 2020.

[41] M. B. Goldring and M. Otero, “Inflammation in osteoarthritis,” *Current Opinion in Rheumatology*, vol. 23, no. 5, pp. 471–478, 2011.

[42] S. Yang, J.-H. Ryu, H. Oh et al., “NAMPT (visfatin), a direct target of hypoxia-inducible factor-2α, is an essential catabolic regulator of osteoarthritis,” *Annals of the Rheumatic Diseases*, vol. 74, no. 3, pp. 595–602, 2015.

[43] D. Kumar, M. Kumar, C. Saravanan, and S. K. Singh, “Curcumin: a potential candidate for matrix metalloproteinase inhibitors,” *Expert Opinion on Therapeutic Targets*, vol. 16, no. 10, pp. 959–972, 2012.

[44] H. S. Hwang and H. A. Kim, “Chondrocyte apoptosis in the pathogenesis of osteoarthritis,” *International Journal of Molecular Sciences*, vol. 16, no. 11, pp. 26035–26054, 2015.

[45] L. Ding, E. Heying, N. Nicholson et al., “Mechanical impact induces cartilage degradation via mitogen activated protein kinases,” *Osteoarthritis and Cartilage*, vol. 18, no. 11, pp. 1509–1517, 2010.

[46] C. Vaamonde-Garcia, R. R. Riveiro-Naveira, M. N. Valcarcel-Ares, L. Hermida-Barbolo, F. J. Blanco, and M. J. López-Armada, “Mitochondrial dysfunction increases inflammatory responsiveness to cytokines in normal human chondrocytes,” *Arthritis and Rheumatism*, vol. 64, no. 9, pp. 2927–2936, 2012.

[47] D. D’Lima, J. Hermida, S. Hashimoto, C. Colwell, and M. Lotz, “Caspase inhibitors reduce severity of cartilage lesions in experimental osteoarthritis,” *Arthritis and Rheumatism*, vol. 54, no. 6, pp. 1814–1821, 2006.

[48] N. Sreejayan and M. N. Rao, “Free radical scavenging activity of curcuminoids,” *Arzneimittel-Forschung*, vol. 46, no. 2, pp. 169–171, 1996.

[49] T. Ak and I. Gülçin, “Antioxidant and radical scavenging properties of curcumin,” *Chemico-Biological Interactions*, vol. 174, no. 1, pp. 27–37, 2008.

[50] M. Soto-Urquieta, E. Franco-Robles, I. Zúñiga-Trujillo, A. Campos-Cervantes, V. Perez-Vazquez, and J. Ramirez-Emiliano, “Curcumin decreases oxidative stress in mitochondria isolated from liver and kidneys of high-fat diet-induced
obese mice,” *Journal of Asian Natural Products Research*, vol. 15, no. 8, pp. 905–915, 2013.

[51] M. Alizadeh and S. Kheirouri, “Curcumin reduces malondialdehyde and improves antioxidants in humans with diseased conditions: a comprehensive meta-analysis of randomized controlled trials,” *Biomedicine (Taipei)*, vol. 9, no. 4, pp. 23–23, 2019.

[52] C. Buhrmann, A. Mobasheri, U. Matis, and M. Shakibaei, “Curcumin mediated suppression of nuclear factor-kB promotes chondrogenic differentiation of mesenchymal stem cells in a high-density co-culture microenvironment,” *Arthritis Research & Therapy*, vol. 12, no. 4, p. R127, 2010.

[53] G. Liang, S. Yang, H. Zhou et al., “Synthesis, crystal structure and anti-inflammatory properties of curcumin analogues,” *European Journal of Medicinal Chemistry*, vol. 44, no. 2, pp. 915–919, 2009.

[54] P. Wang, Y. Ye, W. Yuan, Y. Tan, S. Zhang, and Q. Meng, “Curcumin exerts a protective effect on murine knee chondrocytes treated with IL-1β through blocking the NF-κB/HIF-2α signaling pathway,” *Annals of Translational Medicine*, vol. 9, no. 11, pp. 940–940, 2021.